PRGO Quote, Financials, Valuation and Earnings

Amarin Corp PLC has a net margin of -0.61% compared to Perrigo Co PLC's net margin of -37.36%. Perrigo Co PLC's return on equity of -4.01% beat Amarin Corp PLC's return on equity of -16.98%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 27.68%. On the other hand Amarin Corp PLC has an analysts' consensus of $8.00 which suggests that it could fall by -29.14%. Given that Perrigo Co PLC has higher upside potential than Amarin Corp PLC, analysts believe Perrigo Co PLC is more attractive than Amarin Corp PLC.

Perrigo Co PLC has a beta of 0.448, which suggesting that the stock is 55.199% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.97%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.13%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1B, which are larger than Amarin Corp PLC quarterly revenues of $42M. Perrigo Co PLC's net income of -$6.4M is higher than Amarin Corp PLC's net income of -$15.7M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.86x versus 1.09x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.

Avadel Pharmaceuticals PLC has a net margin of -0.61% compared to Perrigo Co PLC's net margin of -9.37%. Perrigo Co PLC's return on equity of -4.01% beat Avadel Pharmaceuticals PLC's return on equity of -35.57%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 27.68%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.56 which suggests that it could grow by 93.98%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.448, which suggesting that the stock is 55.199% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.743%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.13%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1B, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $52.5M. Perrigo Co PLC's net income of -$6.4M is lower than Avadel Pharmaceuticals PLC's net income of -$4.9M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.86x versus 4.48x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -0.61% compared to Perrigo Co PLC's net margin of -10.31%. Perrigo Co PLC's return on equity of -4.01% beat Jazz Pharmaceuticals PLC's return on equity of 12.12%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 27.68%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $184.76 which suggests that it could grow by 72.66%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.448, which suggesting that the stock is 55.199% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.836%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.13%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1B, which are larger than Jazz Pharmaceuticals PLC quarterly revenues of $897.8M. Perrigo Co PLC's net income of -$6.4M is higher than Jazz Pharmaceuticals PLC's net income of -$92.5M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 14.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.86x versus 1.68x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of -0.61% compared to Perrigo Co PLC's net margin of 11.84%. Perrigo Co PLC's return on equity of -4.01% beat Medtronic PLC's return on equity of 9.51%.

Perrigo Co PLC has a consensus price target of $34.60, signalling upside risk potential of 27.68%. On the other hand Medtronic PLC has an analysts' consensus of $95.84 which suggests that it could grow by 17.97%. Given that Perrigo Co PLC has higher upside potential than Medtronic PLC, analysts believe Perrigo Co PLC is more attractive than Medtronic PLC.

Perrigo Co PLC has a beta of 0.448, which suggesting that the stock is 55.199% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.855%.

Perrigo Co PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 4.13%. Medtronic PLC offers a yield of 3.45% to investors and pays a quarterly dividend of $0.70 per share. Perrigo Co PLC pays -88.77% of its earnings as a dividend. Medtronic PLC pays out 76.98% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co PLC quarterly revenues are $1B, which are smaller than Medtronic PLC quarterly revenues of $8.9B. Perrigo Co PLC's net income of -$6.4M is lower than Medtronic PLC's net income of $1.1B. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 22.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.86x versus 3.12x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.